ANI Pharmaceuticals (US.ANIP)
Capital Allocation Audit · Period: 2010 – 2026
Key Metrics
US.ANIP · YoY: 2026 Q1 vs 2025 Q1
| Metric | Value | YoY |
|---|---|---|
| FCF Conversion | 80.6% | ↑ |
| ROE | 5.2% | ↑ |
| Cash Conversion | 197.9% | ↓ |
| D/E Ratio | 1.09 | ↑ |
| Gross Margin | 60.6% | → |
US.ANIP (ANI Pharmaceuticals) | YoY: 2026 Q1 vs 2025 Q1 Metric Value YoY ---------------------------- FCF Conversion 80.6% ↑ ROE 5.2% ↑ Cash Conversion 197.9% ↓ D/E Ratio 1.09 ↑ Gross Margin 60.6% →
Key Metrics
US.ANIP (ANI Pharmaceuticals) | YoY: 2026 Q1 vs 2025 Q1
Metric Value YoY----------------------------FCF Conversion 80.6% ↑ROE 5.2% ↑Cash Conversion 197.9% ↓D/E Ratio 1.09 ↑Gross Margin 60.6% →Audit Dimensions
Unlimited Companies
AppleMicrosoftAlphabet-AAmazonNVIDIAMeta PlatformsTeslaBerkshire Hathaway-BJPMorganVisaJohnson & JohnsonWalmartProcter & GambleExxon MobilUnitedHealthHome DepotMasterCardPfizerAbbVieCoca-ColaPepsiCoCostcoNetflixAdvanced Micro DevicesSalesforceDisneyNikeBoeingCaterpillarGoldman SachsAlibabaPDD HoldingsJD.comNIO IncLi AutoBaiduTaiwan SemiconductorASML HoldingEli Lilly and CoBroadcomCiscoOracleIntelAT&TVerizonMerck & CoTexas InstrumentsUnited Parcel ServiceRTX CorpLowe's Companies